<?xml version="1.0" encoding="UTF-8"?>
<p>Interestingly, the role of the c3-complement system activation in SARS-CoV-1, SARS-CoV-2-related disorders and HIV-related comorbidities was discussed [
 <xref rid="B62-molecules-25-02944" ref-type="bibr">62</xref>,
 <xref rid="B63-molecules-25-02944" ref-type="bibr">63</xref>,
 <xref rid="B64-molecules-25-02944" ref-type="bibr">64</xref>,
 <xref rid="B65-molecules-25-02944" ref-type="bibr">65</xref>]. According to our results, complement c3 is involved in both inflammation and immune response processes, besides its role as a complement activation. An attempt to combat COVID-19 using the compstatin-based complement c3 inhibitor AMY-101 has been shown recently [
 <xref rid="B65-molecules-25-02944" ref-type="bibr">65</xref>], resulting in a good clinical response. The involvement of c3 complement in the mannose binding lectin-pathway (MBL) was shown during membrane attack complex (MAC) formation, leading to cell lysis and death [
 <xref rid="B66-molecules-25-02944" ref-type="bibr">66</xref>] of HIV-infected patients.
</p>
